Home‎ > ‎


Dave P. Miller is Lead Program Biostatistican
at Genomic Health Inc., Redwood City, CA


Publications (not updated regularly)


1.    Miller DP and Farber HW. “‘Who’ll be the next in line?’ The lung allocation score in patients with pulmonary arterial hypertension.” J Heart Lung Transplant. Dec 2013; 32(12):1165-1167.

2.    McGoon MD, Benza RL, Escribano-Subias, P, Jiang X, Miller DP, Peacock AJ, Pepke-Zaba J, Pulido T, Rich S, Rosenkranz S. “Pulmonary arterial hypertension: epidemiology and registries.” Journal of the American College of Cardiology. Dec 2013;62(25_S).

3.    Frost AE, Badesch DB, Miller DP, Benza RL, Meltzer LA, McGoon MD. “Evaluation of the predictive value of a clinical worsening definition using 2-Year outcomes in patients with pulmonary arterial hypertension: A REVEAL Registry analysis.” Chest. Nov 2013; 144(5):1521-1529.

4.    Farber HW, Miller DP, Meltzer LA, McGoon, MD. “Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional class IV: insights from the REVEAL Registry.” J Heart Lung Transplant. Nov 2013; 32(11):1114-1122.

5.    Au HJ, Eiermann W, Robert NJ, Pieńkowski T, Crown J, Martin M, Pawlicki M, Chan A, Mackey J, Glaspy J, Pinter T, Liu MC, Fornander T, Sehdev S; Ferroro JM, Bee V, Santana MJ, Miller DP, Lalla D, Slamon DJ. “Health-related quality of life with adjuvant docetaxel and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 study.” Oncologist. Jun 28, 2013;18(7): 812-8

6.    Bui QT, Reddy VS, Jacobs JR, Begelman SM, Frederick PD, Miller DP, French WJ. “Previous Myocardial Infarction as a Risk Factor for In-Hospital Cardiovascular Outcomes (from the National Registry of Myocardial Infarction 4 and 5).” The American Journal of Cardiology. Jun 15, 2013; 111(12):1694-700.

7.    Frost AE, Farber HW, Barst RJ, Miller DP, Elliott CG, McGoon MD. “Demographics and outcomes of patients diagnosed with pulmonary hypertension with pulmonary capillary wedge pressures 16 to 18 mm Hg: insights from the REVEAL Registry. Chest. Jan 2013; 143(1):185-195.

8.    Chipps B, Zeiger R, Dorenbaum A, Borish L, Wenzel S, Miller DP, Hayden ML, Bleeker ER, Simons FE, Szefler SJ, Weiss ST, Haselkorn T. “Assessment of asthma control and asthma exacerbations in the epidemiology and natural history of asthma: outcomes and treatment regimens (TENOR) observational cohort.” Current Respiratory Care Reports. Dec 2012; 1(4):259-269.

9.    Kitterman N, Poms AM, Miller DP, Lombardi S, Farber H, Barst RJ. “Bloodstream infections in patients with pulmonary arterial hypertension treated with intravenous prostanoids: insights from the REVEAL registry.” Mayo Clinic Proceedings. Sep 2012; 87(9):825-34.

10.  Miller DP, Gomberg-Maitland M, Humbert M. “Survivor bias and risk assessment.” European Respiratory Journal. Sep 2012; 40(3):530-2.

11.  Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. “An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from REVEAL.” Chest. Aug 2012; 142(2):448-56.

12.  Chipps B, Zeiger R, Borish L, Wenzel SE, Yegin A, Hayden ML, Miller DP, Bleecker ER, Simons FE, Szefler SJ, Weiss ST, Haselkorn T, TENOR Study Group. “Key findings and clinical implications from The Epidemiology and Natural History of Asthma: outcomes and treatment regimens (TENOR) study. Journal of Allergy & Clinical Immunology. Aug 2012; 130(2):332-42.

13.  Krowka MJ, Miller DP, Barst RJ, Taichman D, Dweik RA, Badesch DB, McGoon MD. “Portopulmonary hypertension: a report from the US-based REVEAL registry.” Chest. Jul 21 2012; 141(4):906-15.

14.  McGoon M, Miller DP. “REVEAL: a contemporary US pulmonary arterial hypertension registry.” European Respiratory Review. Mar 2012; 21(123):8-18.

15.  Benza RL, Gomberg-Maitland M, Miller DP, Frost A, Frantz R, Foreman AJ, Badesch DB, McGoon MD. “The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension.” Chest. Feb 2012; 141(2):354-62.

16.  Barst RJ, McGoon MD, Elliott CG, Foreman AJ, Miller DP, Ivy DD. “Survival in childhood pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management.” Circulation. Jan 3, 2012; 125(1):113-122.

17.  Pinto DS, Frederick PD, Chakrabarti AK, Kirtane AJ, Ullman E, Dejam A, Miller DP, Henry T, Gibson CM. “Benefit of transferring ST-segment-elevation myocardial infarction patients for percutaneous coronary intervention compared with administration of onsite fibrinolytic declines as delays increase.” Circulation. Nov 2011; 124(23):2512-21.

18.  Brown L, Chen H, Halpern S, Taichman D, McGoon MD, Farber H, Frost A, Liou TG, Turner MP, Feldkircher K, Miller DP, Elliott CG. “Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL registry.” Chest. Jul 2011; 140:19-26.

19.  Farber H, Foreman AJ, Miller DP, McGoon M. “REVEAL registry: correlation of right heart catheterization and echocardiography in patients with pulmonary arterial hypertension.” Congestive Heart Failure. Mar-Apr 2011; 17(2):56-64.

20.  Burger CD, Foreman AJ, Miller DP, Safford RE, McGoon M, Badesch DB. “Comparison of body habitus in patients with pulmonary arterial hypertension enrolled in the Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL) with normative values from the National Health and Nutrition Examination Survey.” Mayo Clinic Proceedings. Feb 2011; 86(2):105-12.

21.  Chung L, Liu J, Parsons LS, Hassoun P, McGoon M, Badesch DB, Miller DP, Nicolls MR, Zamanian RT. “Characterization of connective tissue disease-associated pulmonary arterial hypertention from REVEAL: identifying systemic sclerosis as a unique phenotype.” Chest. Dec 2010; 138(6):1383-94.

22.  Benza RL, Miller DP, Frost A, Barst RJ, Krichman AM, McGoon MD. “Analysis of the lung allocation score estimation of risk of death in patients with pulmonary arterial hypertension using data from the REVEAL Registry.” Transplantation. Aug 15, 2010; 90(3):298-305.

23.  Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, Frost A, Barst RJ, Badesch DB, Elliott CG, Liou TG, McGoon MD. “Predicting Survival in Pulmonary Arterial Hypertension: Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL).” Circulation. Jul 13, 2010; 122:164-172.

24.  Haselkorn T, Chen H, Miller DP, Fish JE, Peters SP, Weiss ST, Jones CA. “Asthma control and activity limitations: insights from the Real-world Evaluation of Asthma Control and Treatment (REACT) study. Annals of Allergy, Asthma & Immunology. Jun 2010; 104 (6):471-477.

25.  Badesch DB, Raskob GE, Elliott CG, Krichman AM, Farber HW, Frost AE, Barst RJ, Benza RL, Liou TG, Turner M, Giles S, Feldkircher K, Miller DP, and McGoon M. “Pulmonary Arterial Hypertension: Baseline Characteristics from the REVEAL Registry.” Chest. Feb 2010; 137(2):376-387.

26.  Haselkorn T, Fish JE, Zeiger RS, Szefler SJ, Miller DP, Chipps BE, Simons FE, Weiss ST, Wenzel SE, Borish L, Bleecker ER; TENOR Study Group. “Consistently very poorly controlled asthma, as defined by the impairment domain of the Expert Panel Report 3 guidelines, increases risk for future severe asthma exacerbations in The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study.” J Allergy Clin Immunol. Nov 2009; 124(5):895-902.

27.  Miller DP, Tom G, Rasouliyan L, Chipps B. “Patient-reported outcomes among omalizumab and salmeterol/fluticasone combination therapy patients.” Journal of Asthma. Mar 2009; 46(2):179-85.

28.  Haselkorn T, Fish JE, Chipps B, Miller DP, Chen H, Weiss ST. “Effect of weight change on asthma-related health outcomes in patients with severe or difficult-to-treat asthma.” Respiratory Medicine. Feb 2009; 103(2):274-83.

29.  McGoon MD, Krichman A, Farber HW, Barst RJ, Raskob GE, Liou TG, Miller DP, Feldkircher K, Giles S. “Design of the REVEAL registry for US patients with pulmonary arterial hypertension.” Mayo Clin Proc. Aug 2008; 83(8):923-31.

30.  Heddson B, Ronnow K, Olsson M, Miller D. “Digital versus screen-film mammography: a retrospective comparison in a population-based screening program.” European Journal of Radiology. Dec 2007; 64:419-425.

31.  Chen H, Gould MK, Blanc PD, Miller DP, Kamath TV, Lee JH. “Asthma control, severity, and quality of life: quantifying the effect of uncontrolled disease.” J Allergy Clin Immunol. Aug 2007; 120:396-402.

32.  Nallamothu BK, Blaney ME, Morris SM, Parsons LS, Miller DP, Canto JG, Barron HV, Krumholz HM. “Acute reperfusion therapy in ST-elevation myocardial infarction from 1994-2003.” American Journal of Medicine. Aug 2007; 120:693-699.

33.  Miller MK, Lee JH, Miller DP, Wenzel SE; for the TENOR Study Group. “Recent asthma exacerbations: A key predictor of future exacerbations.” Respir Med. Mar 2007; 101: 481-489.

34.  Dauerman HL, Frederick PD, Miller DP, French WJ. “Current incidence and clinical outcomes of bivalirudin administration among patients undergoing primary coronary intervention for stent thrombosis elevation acute myocardial infarction.” Coronary Artery Disease. Mar 2007; 18:141-8.

35.  Padman R, McColley SA, Miller DP, Konstan MW, Morgan WJ, Schechter MS, Ren CL, Wagener JS. “Infant care patterns at epidemiologic study of cystic fibrosis sites that achieve superior childhood lung function.” Pediatrics. Mar 2007; 119(3):e531-7.

36.  Haselkorn T, Borish L, Miller DP, Weiss ST, Wong DA. “High prevalence of skin test positivity in severe or difficult-to-treat asthma.” Journal of Asthma. Dec 2006; 43(10):745-52.

37.  Pinto DS, Kirtane AJ, Nallamothu BK, Murphy SA, Cohen DJ, Laham RJ, Cutlip DE, Bates ER, Frederick PD, Miller DP, Carrozza JP Jr, Antman EM, Cannon CP, Gibson CM. “Hospital delays in reperfusion for ST-elevation myocardial infarction: implications when selecting a reperfusion strategy.” Circulation. Nov 7, 2006; 114(19):2019-25.

38.  Raffy P, Gaudeau Y, Miller DP, Moureaux JM, Castellino RA. “Computer-aided detection of solid lung nodules in lossy compressed multidetector computed tomography chest exams.” Academic Radiology. Oct 2006; 13:1194-203.

39.  Lee JH, Haselkorn T, Chipps BE, Miller DP, Wenzel SE, TENOR Study Group. “Gender differences in IGE-mediated allergic asthma in The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study.” Journal of Asthma. Apr 2006; 43(3):179-84.

40.  Mascia K, Haselkorn T, Deniz YM, Miller DP, Bleecker ER, Borish L, TENOR Study Group. “Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma.” Journal of Allergy & Clinical Immunology. Nov 2005; 116:970-5.

41.  Miller MK, Johnson C, Miller DP, Deniz Y, Bleecker ER, Wenzel SE; TENOR Study Group. “Severity assessment in asthma: An evolving concept.” J Allergy Clin Immunol. Nov 2005; 116(5):990-5.

42.  Miller DP. “Emphasis on CIs when P values are not appropriate.” Radiology. Sep 2002; 224(3):932-3.

43.  Zitter JN, Mazonson PD, Miller DP, Hulley SB, Balmes JR. “Aircraft cabin air recirculation and symptoms of the common cold.” JAMA. Jul 2002; 24-31; 288(4):483-6.

44.  Henke CJ, Villa KF, Aichelmann-Reidy ME, Armitage GC, Eber RM, Genco RJ, Killoy WJ, Miller DP, Page RC, Polson AM, Ryder MI, Silva SJ, Somerman MJ, Van Dyke TE, Wolff LF. “An economic evaluation of a chlorhexidine chip for treating chronic periodontitis: the CHIP (chlorhexidine in periodontitis) study.” The Journal of the American Dental Association. Nov 2001; 132:1557-69.

45.  Mathias SD, Colwell HH, Miller DP, Pasta DJ, Henning JM, Ofman JJ. “Health-related quality-of-life and quality-days incrementally gained in symptomatic nonerosive GERD patients treated with lansoprazole or ranitidine.” Digestive Diseases & Sciences. Nov 2001; 46:2416-23.

46.  Anderson KM, Califf RM, Stone GW, Neumann FJ, Montalescot G, Miller DP, Ferguson JJ 3rd, Willerson JT, Weisman HF, Topol EJ. “Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention.” J Am Coll Cardiol. Jun 15, 2001; 37(8):2059-65.

47.  Pilote L, Miller DP, Califf RM, Topol EJ. “Recurrent ischemia after thrombolysis for acute myocardial infarction.” American Heart Journal. Apr 2001; 141:559-65.

48.  Miller DP, Villa KF, Hogue SL, Sivapathasundaram D. “Birth and first-year costs for mothers and infants attributable to maternal smoking.” Nicotine and Tobacco Research. Feb 2001; 3:25-35.

49.  Grossfeld GD, Chang JJ, Broering JM, Miller DP, Yu J, Flanders SC, Carroll PR. “Does the completeness of prostate sampling predict outcome for patients undergoing radical prostatectomy?” Urology. Sep 2000; 56:430-5.

50.  Brieger DB, Mak KH, Miller DP, Califf RM, Topol EJ. “Hierarchy of risk based on history and location of prior myocardial infarction in the thrombolytic era.” American Heart Journal. Jul 2000; 140:29-33.

51.  Grossfeld GD, Chang JJ, Broering JM, Miller DP, Yu J, Flanders SC, Henning JM, Stier DM, Carroll PR. “Impact of positive surgical margins on prostate cancer recurrence and the use of secondary cancer treatment: data from the CaPSURE database.” Journal of Urology. Apr 2000; 163:1171-7.

52.  Miller DP, Pasta DJ, Mathias SD, Colwell HH, Henning JM. “Quality-days incrementally gained: a new approach for short-term evaluations based on the extended Q-TWiST method illustrated in a clinical study of reflux disease patients.” Drug Information Journal. Apr 2000; 34:469-81.

53.  Mathias SD, Colwell HH, Miller DP, Moreland LW, Buatti M, Wanke L. “Health-related quality of life and functional status of patients with rheumatoid arthritis randomly assigned to receive etanercept or placebo.” Clinical Therapeutics. Jan 2000; 22:128-39.

54.  Narins CR, Miller DP, Califf RM, Topol EJ. “The relationship between periprocedural myocardial infarction and subsequent target vessel revascularization following percutaneous coronary revascularization: insights from the EPIC trial.” Journal of the American College of Cardiology. Mar 1999; 33:647-53.

55.  Kong DF, Califf RM, Miller DP, Moliterno DJ, White HD, Harrington RA, Tcheng JE, Lincoff AM, Hasselblad V, Topol EJ. “Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIB/IIIA integrin in ischemic heart disease.” Circulation. Dec 22-29, 1998; 98:2829-35.

56.  Asher CR, Miller DP, Grimm RA, Cosgrove DM, Chung MK. “Analysis of risk factors for development of atrial fibrillation early after cardiac valvular surgery.” American Journal of Cardiology. Oct 1,1998; 82:892-5.

57.  Chung MK, Schweikert RA, Wilkoff BL, Niebauer MJ, Pinski SL, Trohman RG, Kidwell GA, Jaeger FJ, Morant VA, Miller DP, Tchou PJ. “Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required? Yield of in-house monitoring and prediction of risk for significant arrhythmia complications.” Journal of the American College of Cardiology. Jul 1998; 32:169-76.

58.  Ghaffari S, Kereiakes DJ, Lincoff AM, Kelly TA, Timmis GC, Kleiman NS, Ferguson JJ, Miller DP, Califf RA, Topol EJ. “Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy.” American Journal of Cardiology. Jul 1998; 82:7-12.

59.  Ellis SG, Brown KJ, Ellert R, Howell GL, Miller DP, Flowers NM, Ott PA, Keys T, Loop FD, Topol EJ. “Cost of cardiac care in the three years after coronary catheterization in a contained care system: critical determinants and implications.” Journal of the American College of Cardiology. May 1998; 31:1306-13.

60.  Kereiakes DJ, Lincoff AM, Miller DP, Tcheng JE, Cabot CF, Anderson KM, Weisman HF, Califf RM, Topol EJ. “Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent use, clinical outcomes, and bleeding complications. EPILOG Trial Investigators.” Circulation. March 10, 1998. 97(9):857-64

61.  Sgarbossa EB, Pinski SL, Topol EJ, Califf RM, Barbagelata A, Goodman SG, Gates KB, Granger CB, Miller DP, Underwood DA, Wagner GS. “Acute myocardial infarction and complete bundle branch block at hospital admission: clinical characteristics and outcome in the thrombolytic era.” Journal of the American College of Cardiology. Jan 1998; 31:105-110.

62.  Topol EJ, Ferguson JJ, Weisman HF, Tcheng JE, Ellis SG, Kleiman NS, Ivanhoe RJ, Wang AL, Miller DP, Anderson KM, Califf RM, for the EPIC Investigator Group. “Long-term Protection From Myocardial Ischemic Events in a Randomized Trial of Brief Integrin β3 Blockade With Percutaneous Coronary Intervention.” JAMA. Aug 13, 1997; 278:479-484

63.  Mak KH, Moliterno DJ, Granger CB, Miller DP, White HD, Wilcox RG, Califf RM, Topol EJ. “Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.” J Am Coll Cardiol. 30:1, 171-9, Jul 1997.

64.  Migrino RQ, Young JB, Ellis SG, White HD, Lundergran CF, Miller DP, Granger CB, Ross AM, Califf RM, Topol EJ, for the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I Angiographic Investigators. “End-systolic volume index at 90 to 180 minutes into reperfusion therapy for acute myocardial infarction is a strong predictor of early and late mortality.” Circulation. Jul 1,1997; 96:116-121.

65.  Simpfendorfer C, Kottke-Marchant K, Lowrie M, Anders RJ, Burns DM, Miller DP, Cove CS, DeFranco AC, Ellis SG, Moliterno DJ, Raymond RE, Sutton JM, Topol EJ. “First chronic platelet glycoprotein IIB/IIIA integrin blockade: a randomized, placebo-controlled pilot study of xemilofiban in unstable angina with percutaneous coronary interventions.” Circulation. Jul 1,1997; 96:76-81.

66.  Chung MK, Pogwizd SM, Miller DP, Cain ME. “Three-dimensional mapping of the initiation of nonsustained ventricular tachycardia in the human heart.” Circulation. Jun 3, 1997; 95:2517-27.

67.  Klein AL, Grimm RA, Black IW, Leun DY, Chung MK, Vaughn SE, Murra RD, Miller DP, Arheart KL, for the Acute Investigators. “Cardioversion guided by transesophaegeal echocardiography: the ACUTE pilot study: a randomized, controlled trial. Annals of Internal Medicine. Feb 1, 1997; 126:200-209.

68.  Wang CW, Steinhubl SR, Castellani WJ, Van Lente F, Miller DP, James KB, Young JB. “Inability of serum myocyte death markers to predict acute cardiac allograft rejection.” Transplantation. Dec 27, 1996; 62:1938-41.

69.  Pilote L, Miller DP, Califf RM, Rao JS, Weaver WD, Topol EJ. “Determinants of the use of coronary angiography and revascularization after thrombolysis for acute myocardial infarction.” New England Journal of Medicine. October 17, 1996. 335:16, 1198-205.

70.  Cohen GI, Duffy CI, Klein AL, Miller DP, Cosgrove DM, Stewart WJ. “Color doppler and two-dimensional echocardiolographic determination of the mechanism of aortic regurgitation with surgical correlation.” Journal of the American Society of Echocardiography. Jul-Aug 1996; 9:508-515.

71.  Klein AL, Murray RD, Black IW, Chandra S, Grimm RA, D'Sa AP, Leung DYC, Miller DP, Morehead AJ, Vaughn SE, Thomas JD. “Integrated backscatter for quantification of left atrial spontaneous echo contrast.” Journal of the American College of Cardiology. Jul 1996; 28:222-223.

72.  Fahy GJ, Pinski SL, Miller DP, McCabe N, Pye C, Walsh MJ, Robinson K. “Natural history of isolated bundle branch block.” American Journal of Cardiology. Jun 1996; 77:1185-90.

73.  Omoigui NA, Miller DP, Brown KJ, Annan K, Cosgrove D, Loop F, Topol EJ. “Outmigration for coronary bypass surgery in an era of public dissemination of clinical outcomes” Circulation, January 1, 1996; 93(1):27-33.

74.  Robinson K, Mayer E, Miller DP, Green R, Gupta A, Kottke-Merchant K, Savon S, Selhub J, Nissen S, Topol E, Kutner M, Jacobsen DW. “Hyperhomocysteinemia and vitamin B6 deficiency: common and independent reversible risk factors for coronary artery disease.” Circulation, 92:2825-2830, Nov 15, 1995.

75.  Cosgrove DM, Lytle BW, Taylor PC, Camacho MT, Stewart RW, McCarthy PM, Miller DP, Piedmonte MR, Loop FD. “The Carpentier-Edwards pericardial aortic valve: ten-year results.” Journal of Thoracic & Cardiovascular Surgery. Sep 1995; 110:651-662.

76.  Pilote L, Califf RM, Sapp S, Miller DP, Mark DB, Weaver WD, Gore JM, Armstrong PW, Ohman EM, Topol EJ. “Regional variation across the United States in the management of acute myocardial infarction.” New England Journal of Medicine. 333:565-72, Aug 31, 1995.

77.  Ellis SG, Miller DP, Brown KJ, Omoigui N, Howell GL, Grierson J, Kutner M, Topol EJ. “In-hospital cost of percutaneous coronary revascularization: critical determinants and implications.” Circulation. Aug 15, 1995; 92:741-7.

78.  Heric B, Lytle BW, Miller DP, Rosenkranz ER, Lever HM, Cosgrove DM. “Surgical management of hypertrophic obstructive cardiomyopathy:early and late results.” Journal of Thoracic & Cardiovascular Surgery. Jul 1995; 110:195-206.

79.  Steinbach F, Novick A, Zincke H, Miller DP, Williams RD, Lund G, Skinner DG, Esrig D, Richie JP, deKernion JB, Marshall F, Marsh CL. “Treatment of renal cell carcinoma in von Hippel Lindau disease: a multicenter study.” Journal of Urology. Jun 1995; 153:1812-6.

80.  Butler B, Novick A, Miller DP, Campbell SA, Licht MR. “Management of small unilateral renal cell carcinomas: radical versus nephron-sparing surgery.” Journal of Urology. Jan 1995; 45:34-40.

81.  Manapat AE, McCarthy PM, Lytle BW, Taylor PC, Loop PC, Stewart RW, Rosenkranz ER, Sapp SK, Miller D, Cosgrove DM. “Gastroepiploic and inferior epigastric arteries for coronary artery bypass: early results and evolving applications.” Circulation. Nov 1994; 90:1144-7.

82.  Steinbach F, Stockle M, Griesinger A, Storkel S, Stein R, Miller DP, Hohenfellner R. “Multifocal renal cell tumors: a retrospective analysis of 56 patients treated with radical nephrectomy.” Urology. Nov 1994; 152:1393-6.

83.  Fix J, Isada L, Cosgrove D, Miller DP, Savage R, Blum J, Stewart W. “Do patients with less than 'echo-perfect' results from mitral valve repair by intraoperative echocardiography have different outcomes?” Circulation. Nov 1993; 88:1139-48.

84.  Kelsey SF, Miller DP, Holoblov R, Lu AS, Cowley MJ, Faxon DP, Detre KM, and investigators from the NHLBI PTCA registry. “Results of Percutaneous Transluminal Coronary Angioplasty in Patients >65 Years of Age (from the 1985 to 1986 National Heart, Lung, and Blood Institute's Coronary Angioplasty Registry).” American Journal of Cardiology. 1033-1038, Nov 1, 1990.

Selected Presentations

  1. Miller DP, Farber HW, Poms A, Badesch DB, Muros-Le Rouzic E, Benton WW, McGoon MD. “Five-year outcomes of the registry to evaluate early and long-term pulmonary hypertension (PAH) disease management (REVEAL).” Accepted to be presented at: American Thoracic Society; 2014; San Diego, CA.

  2. Miller DP. “Risk Prediction, Observational Studies, and PAH.” Presented by invitation with grant support from Scleroderma Center of Research Translation, Boston University; 2013; Boston, MA.

  3. Miller DP, Foreman AJ. “Estimating survival from diagnosis when study enrollment is after time of diagnosis: a left truncation case study.” Presented at: International Conference of Pharmacoepidemiology; 2011; Chicago, IL.

  4. Miller DP, Foreman AJ. “Application of left truncation survival methods in a large disease registry: a case study with practical implications.” Presented at: Joint Statistical Meeting; 2010; Vancouver, BC, Canada.

  5. Miller DP, Rasouliyan L. “Publishing the results of observational studies.” Workshop at: 11th Annual Registries and Post-Approval Studies Conference of the Centers for Business Intelligence; 2008; Washington DC.

  6. Miller DP, Rasouliyan L. “Observational study data analysis: when your goal is publication rather than a regulatory filing.” Workshop at: 10th Annual Registries and Post-Approval Studies Conference of the Centers for Business Intelligence; 2007; Parsippany, NJ.

  7. Miller DP. “Bootstrap 101: obtain robust confidence intervals for any statistic.” Presented at: 29th Annual SAS Users Group International Conference; 2004; Montreal, QC, Canada.

  8. Miller DP, Colwell HH, Pritchard ML, Calhoun JC, Calhoun EA. “Xerostomia symptoms: a newly developed patient-reported outcomes questionnaire.” Presented at: 9th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research; 2004; Arlington, VA.

  9. Miller DP, Burns R, Schneider A, O'Shaughnessy, Wood S, Castellino RA. “A multi-reader, multi-case ROC study demonstrating improved performance detecting lung nodules using computer-aided detection (CAD) in multi-slice CT (MSCT) of the chest.” Presented at: 89th Scientific Assembly and Annual Meeting of the
    Radiological Society of North America; 2003; Chicago, IL.

  10. Rao JS, Miller DP, and Potts W. "Uses for classification trees for biomedical and clinical trial data: when is instability a problem, and can it be helped?" Presented at: ENAR; March 1998; Pittsburgh, PA (co-presented with Sunil Rao).

  11. Miller DP. “Application of a CART model in a logistic regression setting.” Presented at: Joint Statistical Meetings; August 1995; Orlando, FL.

  12. Miller DP, Rao S, Omoigui N. “Hospital cost as a primary outcome: practical analysis experience.” Presented at: ENAR; March 1995; Birmingham, AL.

  13. Miller DP, Kalton G, Lepkowski JM. “Estimating duration of food stamp spells from the SIPP.” Presented at: American Statistical Association Winter Meeting; January 1993; Ft Lauderdale, FL.



Return to davepmiller HOME